You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NK Immunotherapy

Showing 1 - 25 of 4,100
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Trial (NK cells, Talazoparib 1 MG [Talzenna])

Not yet recruiting
  • Acute Myeloid Leukemia
  • NK cells
  • Talazoparib 1 MG [Talzenna]
  • (no location specified)
Jan 9, 2023

Malignant Sarcoma Trial in Madrid (Natural Killer (NK) cells (a new immunotherapy))

Recruiting
  • Malignant Sarcoma
  • Natural Killer (NK) cells (a new immunotherapy)
  • Madrid, Spain
    Hospital Universitario La Paz
Jul 19, 2023

Immunotherapy, Multiple Myeloma Trial in Zhengzhou (Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK))

Recruiting
  • Immunotherapy
  • Multiple Myeloma
  • Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Dec 14, 2022

Neuroblastoma Recurrent Trial in Hong Kong (Natural killer cell, Dinutuximab beta, Interleukin-2)

Recruiting
  • Neuroblastoma Recurrent
  • Natural killer cell
  • +4 more
  • Hong Kong, Hong Kong
    Hong Kong Children's Hospital
Feb 22, 2023

Gastroesophageal Junction (GEJ) Cancers, Advanced HNSCC Trial run by the NCI (N-803, Pembrolizumab, PD-L1 t-haNK)

Recruiting
  • Gastroesophageal Junction (GEJ) Cancers
  • Advanced HNSCC
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 26, 2023

Pediatric Sarcoma, Refractory, Pediatric Sarcoma, Relapsed Trial in Tampa, Columbus (GEM/DOX + TGFBi expanded NK cells)

Recruiting
  • Pediatric Sarcoma, Refractory
  • Pediatric Sarcoma, Relapsed
  • GEM/DOX + TGFBi expanded NK cells
  • Tampa, Florida
  • +1 more
Jan 3, 2023

Colon Cancer, Resected Stage Trial in Houston (Cetuximab, CB-NK-TGF-βR2-/NR3C1, Fludarabine phosphate)

Recruiting
  • Colon Cancer
  • Resected Stage
  • Houston, Texas
    M D Anderson Cancer Center
Jul 23, 2022

NSCLC Trial in Xinxiang (CCCR-NK92 cells)

Enrolling by invitation
  • Non-small Cell Lung Cancer
  • CCCR-NK92 cells
  • Xinxiang, Henan, China
    The first Affiliated Hospital of Xinxiang Medical University
Aug 31, 2022

Acute Myeloid Leukemia Trial in Pittsburgh (Neukoplast™ (NK-92))

Completed
  • Acute Myeloid Leukemia
  • Neukoplast™ (NK-92)
  • Pittsburgh, Pennsylvania
    UPMC Cancer Center - Hillman Cancer Center
Mar 28, 2022

Acute Myeloid Leukemia Trial in Minsk (NK cell infusions)

Recruiting
  • Acute Myeloid Leukemia
  • NK cell infusions
  • Minsk, Minsk Region, Belarus
    Belarussian Research Center for Pediatric Oncology, Hematology a
Feb 28, 2022

Following Treatment With Fate Therapeutics' Engineered Cellular

Terminated
  • Hematological Malignancy
  • Genetically engineered NK cells
  • Phoenix, Arizona
  • +4 more
Aug 24, 2022

Acute Myeloid Leukemia Trial in Minsk (Expanded haploidentical NK cells)

Recruiting
  • Acute Myeloid Leukemia
  • Expanded haploidentical NK cells
  • Minsk, Minsk Region, Belarus
    Belarussian Research Center for Pediatric Oncology, Hematology a
Apr 12, 2022

Malignant Solid Tumour Trial in Guangzhou (Bevacizumab, NK immunotherapy)

Completed
  • Malignant Solid Tumour
  • Guangzhou, Guangdong, China
    Fuda cancer institute of Fuda cancer hospital
Sep 10, 2020

Ewing Sarcoma, Neuroblastoma, Rhabdomyosarcoma Trial in Milwaukee (Allogeneic HCT, Donor NK Cell Infusion)

Active, not recruiting
  • Ewing Sarcoma
  • +4 more
  • Allogeneic HCT
  • Donor NK Cell Infusion
  • Milwaukee, Wisconsin
  • +1 more
Apr 5, 2022

Multiple Myeloma Trial in Boston (CIML NK Cells plus KP1237 and low dose IL-2)

Recruiting
  • Multiple Myeloma
  • CIML NK Cells plus KP1237 and low dose IL-2
  • Boston, Massachusetts
    Dana Farber Cancer Institute
Jan 18, 2022

Acute Myeloid Leukemia Trial in Bayreuth, Chemnitz, Dresden (NK cells, Cytarabine)

Terminated
  • Acute Myeloid Leukemia
  • Bayreuth, Germany
  • +2 more
Aug 10, 2021

Covid19 Trial (KDS-1000, Placebo)

Withdrawn
  • Covid19
  • KDS-1000
  • Placebo
  • (no location specified)
Aug 24, 2021

NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma Trial in San Francisco, Valhalla (Methotrexate, pralatraxate,,

Recruiting
  • NK-Cell Lymphoma
  • +2 more
  • San Francisco, California
  • +1 more
Sep 1, 2021

Malignant Solid Tumour Trial in Guangzhou (Pembrolizumab, NK immunotherapy)

Completed
  • Malignant Solid Tumour
  • Guangzhou, Guangdong, China
    Cancer Institute in Fuda Cancer Hospital
May 26, 2020

COVID Trial in Bogotá, Bogota (Allogeneic NK transfer)

Withdrawn
  • COVID
  • Allogeneic NK transfer
  • Bogotá, Bogotá Distrito Capital, Colombia
  • +1 more
Apr 29, 2021

Long-term, Non-interventional, Observational Study Following

Recruiting
  • Advanced Solid Tumor
  • +17 more
  • Allogeneic natural killer (NK) cell
  • San Diego, California
  • +3 more
Oct 15, 2021

Mantle Cell Lymphoma, Recurrent DLBCL, Recurrent Follicular Lymphoma Trial in Houston (procedure, drug, biological)

Completed
  • Mantle Cell Lymphoma
  • +6 more
  • Autologous Hematopoietic Stem Cell Transplantation
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 18, 2022

B Cell Leukemia, B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia Trial in Guangzhou (CAR-ITNK cells)

Recruiting
  • B Cell Leukemia
  • +4 more
  • CAR-ITNK cells
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
Feb 6, 2021

Acute Myeloid Leukemia, MDS Trial in Basel (NK-DLI)

Recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndromes
  • NK-DLI
  • Basel, Switzerland
    University Hospital Basel
Dec 1, 2020

Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma, MALT Trial in Duarte (biological, procedure,

Active, not recruiting
  • Adult Grade III Lymphomatoid Granulomatosis
  • +23 more
  • autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Jan 4, 2023